Patents Assigned to Pulmonem Inc.
  • Method of treating a person afflicted with COVID-19 and pharmaceutical formulation including dapsone
    Patent number: 11826323
    Abstract: A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.
    Type: Grant
    Filed: September 28, 2022
    Date of Patent: November 28, 2023
    Assignee: PULMONEM INC.
    Inventors: Houfar Sekhavat, Satish Asotra
  • Dapsone formulations and methods of using same
    Patent number: 11337939
    Abstract: A method for treating patients with COVID-19 and/or other respiratory conditions include administering a dosage of 75-100 milligrams of dapsone twice daily. A variety of dapsone formulation and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: May 24, 2022
    Assignee: Pulmonem Inc.
    Inventors: Houfar Sekhavat, Satish Asotra